In summary, we show that TAAR1 agonists as a class, including the clinical drug-candidate ulotaront, not only lack APD-induced metabolic liabilities but can reduce body weight and improve glycemic control in rodent models of diabetes, obesity, and/or iatrogenic weight gain. Here, TAAR1 is linked to diabetes mellitus.